Welcome, New MassBio Members!
Institute of Contemporary Art
The Institute of Contemporary Art strives to share the pleasures of reflection, inspiration, provocation, and imagination that contemporary art offers through public access to art, artists, and the creative process. The primary activities of the ICA are threefold: To present outstanding contemporary art in all media, including visual art exhibitions, music, film, video, and performance, that is deserving of public attention and has not been presented in depth to Boston audiences. To provide innovative experiential learning opportunities for people of all ages through direct encounters with artists and art-making. To design interpretative programs that provide context for, develop appreciation of, and add meaning to contemporary art and culture.
Zymeworks has developed the ZymeCAD™ molecular simulation engine for protein modeling and structure-guided optimization with the unparalleled ability to relate the functional and biophysical characteristics of a protein to its structure. The proprietary insight generated by the ZymeCAD™ engine enables Zymeworks to engineer knowledge-based structural modifications that result in new or improved protein-based drugs.
Kyn Therapeutics was founded by Professor George Georgiou, Ph.D. at the University of Texas, Austin and funded in March 2016 by OrbiMed and Atlas Venture. Kyn is building a leading immune-oncology company with the primary program focused on the clinically validated IDO/TDO immunosuppressive pathway. IDO and TDO are metabolic enzymes overexpressed in many cancers that convert tryptophan to kynurenine. Kynurenine accumulates in the tumor microenvironment where it enters immune cells and binds the aryl hydrocarbon receptor (AHR) triggering broad immunosuppression. Kynurenine signaling affects multiple cell types in the innate and adaptive immune system and inhibiting this pathway unleashes the immune system to attack the tumor. Kyn Therapeutics is developing a novel approach to target both IDO and TDO mediated immunosuppression through enzymatic degradation of kynurenine systemically and in the tumor microenvironment. This approach is differentiated from the current inhibitors in the clinic that only target IDO expressing tumors. Inhibiting the IDO/TDO pathway is expected to have broad application across many tumor types.
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines. Our goal is to interrogate and exploit the vast and largely unexplored transcriptome—the full collection of RNAs transcribed from DNA—to discover small-molecule medicines that target RNA at key disease intervention points. Arrakis is developing a product engine to produce a pipeline of RNA-targeted small-molecule medicines focused in neurology, oncology, and rare genetic disorders. Arrakis has designed two scientific platforms—TRYST™ and PEARL-seq™—to help unlock this unexplored biological space by enabling us to identify tractable RNA targets, design drug molecules, and select candidates for clinical development. A major current focus of our effort is mRNA, especially those that encode therapeutically compelling but “undruggable” proteins, and especially when an effective medicine requires oral bioavailability, blood-brain barrier transport, or frequent dosing. These attributes are difficult to achieve with current RNA-targeted therapies. Arrakis has brought together scientific leaders in RNA structure, chemistry, and biology to work alongside a highly experienced management team with a track record of building transformative biopharmaceutical companies and developing novel therapeutics.
AYOXXA Biosystems, an international biotech company based in Cologne (Germany), Boston (USA) and Singapore, has developed LUNARIS™, an innovative technology that enables multiplex protein analysis of precious, small-volume specimens. This powerful system uses antibody-coated microbeads securely captured on the surface of proprietary BioChips and requires only 3 µL of input sample. LUNARIS™ offers a reliable, precise and accurate immunoassay for multiple biomarkers for both basic and clinical research. Focus areas for this technology include, but are not limited to ophthalmology, mouse-to-man studies and immunooncology. AYOXXA stands for leveraging success in proteomics.
Founded in 2015 by Dr. Tyler Jacks, head of the Koch Institute at MIT, Bill Haney, a longtime tech entrepreneur and investor, and Dr. David Raulet, one of the world's leading experts in Natural Killer (NK) cell biology, Dragonfly Therapeutics develops novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system. Dragonfly's therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses, and are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies – such as T cell treatments.
CN Bio Innovations Limited
CN Bio develops human organ-on-chip technologies: devices that enable the formation of miniature models of human organs in the lab. We provide products and services to the pharmaceutical industry and in the past 3 years have used our proprietary organ-on-chip models in drug discovery and drug safety programs with more than 25 pharmaceutical companies. CN Bio has also pursued research to develop disease organ-on-chip models with successful programmes resulting in novel models of non-alcoholic steatohepatitis and Hepatitis B virus infection.
McCarter & English
McCarter & English brings decades of experience in the pharmaceutical, medical device, biotechnology, and Health Care fields to both established and start-up life sciences ventures. The McCarter & English knowledge base in these industries has earned our firm "a seat at the table" when these companies make far-reaching decisions ranging from structuring clinical trials and raising venture capital, to pursuing in-depth research into ground-breaking medicines and devices, to protecting the valuable Intellectual Property that feeds the long-term success of these enterprises.
TriNet delivers HR outsourcing services that allow small companies to do what they do best. Over 2,000 companies have turned to TriNet for human resources, benefits, payroll, workers compensation, and strategic HR services. As their trusted HR advisor, TriNet helps these organizations contain HR costs, minimize employer-related risks, and relieve the administrative burden of HR.